NLRP3 and myocardial infarction: Colchicine, administered at high doses (0.1 mg/kg per day) for 7 days in the AMI mouse model, significantly inhibited NLRP3 inflammasome expression and activation, indicated by reduced NLRP3, ASC, and caspase-1 levels in the MI area; decreased infarct size; alleviated LV remodeling; protected contractile function; and significantly delayed HF development and 7-day survival after MI (129).